TRAIP enhances progression of tongue squamous cell carcinoma through EMT and Wnt/β-catenin signaling by interacting with DDX39A

TRAIP enhances progression of tongue squamous cell carcinoma through EMT and Wnt/β-catenin signaling by interacting with DDX39A | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article TRAIP enhances progression of tongue squamous cell carcinoma through EMT and Wnt/β-catenin signaling by interacting with DDX39A Litong Liu, ping Wang, cheng Guo, li Song, lifang Chen, hongbin Qi, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4266683/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 02 Dec, 2024 Read the published version in BMC Cancer → Version 1 posted 4 You are reading this latest preprint version Abstract Background Tongue squamous cell carcinoma (TSCC) is one of the most common malignant tumors with high mortality and poor prognosis. Its incidence rate is increasing gradually. Tumor necrosis factor receptor-associated factor interacting protein (TRAIP), as a factor related to several tumors, reveals that its gene expression is different between normal tissue and primary tumor of head and neck squamous cell carcinoma using bioinformatics analysis. Method In our study, TCGA database, immunohistochemistry, proliferation assay, colony formation, wound healing assay, Transwell, cell cycle analysis and tumor xenografts model were used to determine the expression and functions of TRAIP in TSCC. Result We found that TRAIP may promote the proliferation, migration and invasion of TSCC. Furthermore, the results of bioinformatics analysis, mass spectrometry and co-immunoprecipitation suggested that DDX39A may be a TRAIP interacting protein. DDX39A has been proven to be an oncogene in several tumors, which may have an important effect on cell proliferation and metastasis in multiple tumors. In addition, the high expression of DDX39A implies the poor prognosis of patients. Our study demonstrated that TRAIP probably interact with DDX39A to regulate cell progression through epithelial-mesenchymal transition and Wnt/β-catenin pathway. Conclusion These results indicate that TRAIP is important in occurrence and development of TSCC and is expected to become the new promising therapeutic target. TRAIP Progression Tongue squamous cell carcinoma Wnt/β-catenin signaling EMT DDX39A Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Introduction Oral cancer is a highly prevalent cancer worldwide, and more than 90% of the cases are squamous cell carcinoma[ 1 ], which is the most common malignant tumor of the head and neck[ 2 ]. Tongue cancer is a branch of head and neck cancer. The incidence rate of tongue squamous cell carcinoma (TSCC) gradually increases, especially in young patients[ 3 ]. Many cases were diagnosed in advanced stage because of lack of symptoms[ 4 ]. Early regional lymph nodes metastasis and unsatisfactory chemotherapeutic treatment are also related to high mortality[ 5 ]. Despite various treatments, the long-term prognosis of TSCC is poor, and the 5 year survival rate is about 50%[ 6 ]. The survivors also have many severe disabilities, such as swallowing and speech disorders[ 7 , 8 ]. Therefore, finding effective targeted therapeutic molecules to TSCC is urgently needed. Tumor necrosis factor receptor-associated factor interacting protein (TRAIP) is a ring-dependent E3 ubiquitin ligase, it’s a 53-kDa protein, with a 55-aminoacid-long ring domain at its N-terminal end, a putative coiled-coil domain and a leucine zipper region[ 9 ]. Through bioinformatic analysis, we found that the expression of TRAIP in head and neck squamous cell carcinoma (HNSC) was remarkably higher than that of normal tissues. Previous reports have pointed that TRAIP involves cell progression of many tumors[ 10 – 13 ]. TRAIP is highly expressed in liver cancer, and such overexpression encouraged malignant behavior of liver cancer cells[ 10 ]. In a previous study, TRAIP defective homozygous mouse died in the early embryonic stage because of proliferation defect and excessive cell death[ 14 ]. The overexpression of TRAIP enhanced the proliferation, metastasis, and invasion ability of lung cancer cells[ 11 ]. Interacting with CYLD, TRAIP serves as a tumor suppressor in basal cell carcinoma[ 15 ]. TRAIP improves the invasion and proliferation abilities of osteosarcoma and triple negative breast cancer[ 12 , 13 ]. Therefore, we hypothesize that TRAIP may be a new target in TSCC. However, no research has been conducted on the relationship between TRAIP and TSCC. Bioinformatics is a field that uses mathematics, information technology, statistics and computer science to research biological questions. At present, several bioinformatics databases can be used to analyze proteins sequence, structure and functions[ 16 ]. Therefore, we used bioinformatics to analyze the relationship between TRAIP and TSCC, and to verify the results. Our study found that TRAIP regulated the proliferation and invasion of TSCC cells by interacting with DDX39A. The Wnt signaling pathway and epithelial-mesenchymal transition (EMT) play important roles in the progression of oral cancer[ 17 ]. We further investigated the relationship among TRAIP, DDX39A, Wnt/β-catenin and EMT. These results indicate that TRAIP may be a new potential target in TSCC treatment. Materials and methods TRAIP gene expression analysis We obtained the expression of TRAIP in different normal tissues from the Human Protein Atlas (HPA) database ( https://www.proteinatlas.org/ )[ 18 ]. Unpaired and paired HNSC data from TCGA database joint GTEx database and one datasets (GSE160042[ 19 ]) containing TSCC tissue and normal tissue samples from Gene Expression Omnibus (GEO) database ( https://www.ncbi.nlm.nih.gov/geo/ )[ 20 ] were analyzed and boxplots were drawn. The pROC[ 21 ] package and ggplot2 package were used for plotting ROC curve. We obtained the variation information of TRAIP in patients with HNSC from TCGA database by using cBioPortal ( https://www.cbioportal.org/ ). Enrichment analysis TRAIP expression levels were grouped (transcripts per million (TPM) data, Low TRAIP: 0%-50%. High TRAIP: 50%-100%) and differential analysis was performed using DESeq2[ 22 ] package to obtain differential genes, screen protein coding genes and draw volcano maps. GSEA was analyzed by using clusterProfiler[ 23 ] package (the number of calculations was 10000, and the gene set ranged from 10 to 1000, p.adj < 0.05, FDR 1.8, species: homo sapiens). TRAIP downstream molecular screening Through the same processing as before, the mass spectrometry, HNSC-related differential genes and TRAIP-related differential genes were intersected to obtain the genes that were simultaneously related to HNSC and TRAIP and were screened in the mass spectrometry. TRAIP related proteins were obtained by co-immunoprecipitation (CO-IP), and then the samples were used for mass spectrometry test. The mass spectrometry was finished by Shanghai OE Biotechnology Company (Shanghai, China). The results are shown in supplementary material (Table S3 and S4). We selected several genes related to cancer cell proliferation and invasion from the mass spectrometry results. These genes were input into the STRING ( https://string-db.org/ ) for molecular interaction analysis. The heatmap and scatter plot of the correlation between these genes and TRAIP were drawn by ggplot2. These results suggested that TRAIP may interact with other genes in TSCC, which need further verification. Specimens and cell culture Sixty-five TSCC tissues, corresponding adjacent normal tissues and related clinical characteristics (Table 1) were collected at the Affiliated Hospital of Qingdao University between 2014 and 2016. Specimens from cancer tissue and adjacent normal tissue were obtained during surgery and were immediately dipped in 10% formalin for immunohistochemistry (IHC). No patients received radiotherapy or chemotherapy before surgery. Nine pairs of fresh cancer and adjacent tissue collected at the Affiliated Hospital of Qingdao University were immediately frozen in liquid nitrogen and stored for protein analysis. All patients have signed the informed consent document. The study was approved by the Institutional Medical Ethics Committee of the Qingdao University Affiliated Hospital. Human TSCC cell lines were obtained from Culture Collection of Chinese Academy of Science (Shanghai, China). CAL27 is known to be an adenosquamous cell carcinoma, in the following decades after CAL 27 cell line was established, it has been widely used to build OSCC models for studies in vitro and in vivo and thus regarded as a representative cell line for OSCC studying. All cell lines were tested and characterized using STR profiles and were regularly evaluated for mycoplasma. The cells were cultured in Dulbecco modified Eagle’s medium (DMEM, Gibco, New York, USA) containing 10% fetal bovine serum (Transgen Biotech, Beijing, China), penicillin (100 units/ml) and streptomycin(100mg/ml) at 37℃ in 5% CO 2 . Immunohistochemistry (IHC) The operating steps of IHC staining were introduced previously[ 24 ]. After deparaffinization and hydration, the slides were inactivated endogenous peroxidase by using 3% hydrogen peroxide and heat-pretreated in ethylene diamine tetraacetic acid (pH 8.0) for 5 min by using a microwave oven. Then the anti-TRAIP antibody (Abcam, United Kingdom, dilution at 1:300, 4°C, overnight) and the sheep anti-rabbit antibody (Abcam, dilution at 1:100, 37°C, 30min) were incubated. Sections thickness was set at 4µm, stained with diaminobenzidine (DAB) and counterstained with hematoxylin. Phosphate-buffered saline (PBS) acts as negative control (NC). The results of IHC staining were scored in accordance with staining intensity and percentage of positive tumor cells. The total score contains the staining intensity (0, none; 1, weak; 2, intermediate; 3, strong) and tumor cell positive ratio (0, none; 1, 2/3). Cell transfection Lentiviral-transduced shRNA interference was performed to inhibit TRAIP and DDX39A expression. The lentivirus was purchased from GenePharma (GenePharma, China) and Genechem (Genechem, China). CAL27 and SCC15 cells were transfected with shTRAIP and shDDX39A, and SCC9 was transfected with oeTRAIP and oeDDX39A. CAL27 and SCC15 cells with TRAIP and DDX39A suppressed contained shTRAIP and shDDX39A, SCC9 with TRAIP and DDX39A overexpressed contained oeTRAIP and oeDDX39A, the control group was transfected with NC RNA. 4×10 4 cells were cultured in 6-well plates with 10% fetal bovine serum until 70%-80% of the plates’ bottom was carpeted. After transfection with lentivirus in DMEM for 24h, the culture medium was replaced with complete growth medium with 10% fetal bovine serum. Cells were cultured in medium containing puromycin after 48h for follow-up experiments. All relative sequences are listed in Table S1 . Western blot After covering the bottom surface of T25 culture flask, about 5×10 6 cells were used to extract proteins. Western blot assay was performed as described previously[ 24 ]. The following antibodies were used in this study: anti-TRAIP (Proteintech Group, Inc., Chicago, USA, dilution at 1:1000), anti-β-actin (Proteintech Group, Inc., Chicago, USA, dilution at 1:4000), anti-DDX39A, anti-E-cadherin, anti-N-cadherin, anti-Vimentin, anti-Slug, anti-Snail, anti-MMP2, anti-MMP9, anti-P-β-catenin, anti-β-catenin, anti-c-Myc, anti-cyclinD1 (Abclonal Technology, China, dilution at 1:1000). The stripe gray value of the target protein was measured using Image J and divided by the gray value of the reference protein for normalization. Then the obtained values were homogenized with reference to the control group data, and the expression trend value can be obtained. CAL27, SCC15 and SCC9 were used for western blot assay. Co-IP After covering the bottom surface of the petri dish with a diameter of 10cm, about 10 7 cells were disposed accordance with the Co-IP kit instructions (Takara Biotechnology, Japan). Then, 10µl of 5× loading buffer was added into the protein, and the mixture was boiled for 15 min. The protein-protein complexes were later subjected to western blot and IgG was used as a NC. CAL27, SCC15 and SCC9 were used for Co-IP experiment. Proliferation assay A total of 2000 cells in 100µl complete growth medium were seeded in 96-well plates and cultured separately for 1,2,3,4,5 days in an incubator before 10µl of CCK-8 solution was added in each well for 1h. The optical density value was detected at 450nm by using a microplate reader. Each experiment was repeated three times. CAL27, SCC15 and SCC9 were used for proliferation assay. Migration and invasion assays In testing the migration ability of CAL27, SCC15 and SCC9, 5× \({10}^{5}\) cells in 100µl of serum-free medium were added in upper Transwell chambers. The lower chamber was loaded with 500µl of culture medium containing 30% fetal bovine serum. After incubating CAL27, SCC15 and SCC9 for 21, 15, and 17h respectively, a cotton swab was used to wipe off cells in the upper chamber. The lower surface of Transwell chamber was immerged in 4% paraformaldehyde for 25 min and then dyed with 0.1% crystal violet. In completing cells’ invasion assay, the inner surface of the Transwell chamber was laid with 100µl of diluted Matrigel (Corning, USA) and placed in an incubator for 1h. The 5× \({10}^{5}\) cells were added into the upper Transwell chamber and incubated for 27, 22 and 23h for CAL27, SCC15 and SCC9, respectively. The rest of the steps were basically the same as describedpreviously. The total number of cells on the lower surface counted by Image J was regarded as the number of migrated cells. Colony formation assays TSCC cells were digested by pancreatin and counted by using a cell counting plate. The 1 \(\times {10}^{3}\) cells on a single-cell suspension condition in a 2ml culture medium were inoculated in 6-well plates. After being incubated for 14 days, the inner surface of the plate was immerged in 4% paraformaldehyde for 25 min and then dyed with 0.1% crystal violet. The colony number was calculated. CAL27, SCC15 and SCC9 were used for colony formation assays. Wound healing assays TSCC cells were seeded in 6-well plates and incubated until cells covered the bottom surface of plates. The inner surface cells were scratched using 200µl pipette tip to create straight lines and then washed 3 times with PBS to eliminate detached cells. Then the cells were cultured in incubator with serum-free medium for 24h. Wound area pictures of 0h and 24h were taken. The migration ability of cells is evaluated by measuring the area changes of the injured area using Image J in accordance with the following: scratch closure rate (%) = (injured area of 0h - injured area of 24h) / injured area of 0h \(\times 100\text{\%}\) . CAL27, SCC15 and SCC9 were used for wound healing assays. The experiment was repeated 3 times. Tumor xenografts in nude mice Nude mouse tumorigenesis experiment is a common experiment to study the biological characteristics of human tumors and tumor treatment. And the transplanted nude mouse tumor model has the advantages of high tumor formation rate, good uniformity, and could more accurately reflect the biological characteristics of the tumor cells. Six-week-old BALB/c nude mice were used for subcutaneous tumor implantation experiments. The 1 \(\times {10}^{6}\) CAL27 cells of the NC group and experimental group resuspended in 100µl of PBS (phosphate buffer) and mixed with equal volume of Matrigel (8.1mg/ml) were implanted to the right flank of each nude mouse subcutaneously for 6 weeks. The tumor was measured using a ruler each week. The tumor volume didn’t reach 1500 \({mm}^{3}\) before the deadline of 6 weeks in accordance with the following formula: volume = 1/2 \(\times\) length \(\times\) width 2 . For the lung metastasis model, 1 \(\times {10}^{6}\) cells were injected into the tail vein of nude mice. Six weeks later, mice were euthanized by cervical dislocation and the lung tissues were anatomized and analyzed by HE staining. The research protocol was approved by the Qingdao University Laboratory Animal Welfare Ethics Committee. Cell cycle analysis Cells were seeded in 6-well plates for 24h and then collected to 15ml centrifugal tubes. After centrifugation at 1000g and 4℃ for 5 min, cells were washed by precooled PBS and centrifugated at the abovementioned condition. Cells were resuspended with 70% ethanol and placed in refrigerator at 4℃ for at least 2h. After being resuspended with 250µl of binding buffer and adjusted to the concentration of 1 \(\times {10}^{6}\) /ml, the cells were stained using propidium iodide (PI) and RNase for 15min in darkness before being analyzed using a flow cytometer (Beckman Coulter, Inc., USA). CAL27, SCC15 and SCC9 were used for cell cycle analysis. Statistical analysis All data were analyzed using GraphPad Prism 8.3.0 (GraphPad Software Inc., San Diego, CA, USA). The results are expressed as the mean ± standard error of the mean. The results of two groups were compared using two-tailed Student t-test and three groups or more were compared using one-way ANOVA. The association of TRAIP and patient clinicopathologic characteristics was estimated using Wilcoxon rank-sum test. Statistical significance was marked using “*” to indicate P < 0.05. Results TRAIP expression is upregulated in human TSCC tissues Using the Human Protein Atlas (HPA) database, we found that TRAIP was expressed in various normal tissues (Fig. 1 A). This result suggested that TRAIP expression is lower in normal tongue tissue and higher in testis, bone marrow or thymus. We further assessed the TRAIP expression level in HNSC using TCGA joint GTEx and GEO data and found that the expression level of TRAIP is all significantly higher in HNSC tissue than in normal tissue (Fig. 1 B-D). These results indicated a correlation between the high expression level of TRAIP and the tumorigenesis of HNSC. Based on the ROC curve, the cut-off value, AUC, sensitivity, specificity and Youden index were 2.284, 0.897, 0.743, 0.977 and 0.720, respectively (Fig. 1 E). These abovementioned data indicated that TRAIP may play an important role in HNSC diagnosis. We further studied the correlations between TRAIP expression and patient clinicopathological characteristics in human TSCC. The TRAIP expression in 9 pairs of fresh TSCC tumors and adjacent tissues was detected using western blot. The results suggested that TRAIP expression in tumor tissues was significantly higher than that in adjacent tissues, which indicated that TRAIP was up regulated in TSCC (P < 0.01, Fig. 1 F). Meanwhile, IHC findings showed that the expression level of TRAIP in TSCC tissues was higher than that in adjacent tissues (Fig. 1 G). TRAIP was located in the cytoplasm and cell membrane. The immuno-staining is strongly positive in lymph node metastasis than in primary tumor tissues (Fig. 1 G). In addition, the TRAIP expression level was higher in the primary tumors with lymph node metastasis than that without lymph node metastasis (Fig. 1 G). As shown in table 1, no significant association was observed between TRAIP expression and patients’ gender, age and gross tumor type (P > 0.05). However, the expression level of TRAIP evidently increased in stage III/IV compared with stage I/II, in carcinoma compared with adjacent tissue, in poor differentiation compared with well differentiation, in tissues with recurrence compared with those without recurrence, and in tissues with lymph node metastasis compared with thosewithout lymph node metastasis (P < 0.05). TRAIP promotes TSCC cell proliferation and invasion A total of 19577 protein coding genes were obtained in TRAIP expression grouping (except TRAIP) and the volcano maps are shown in Figure S1 A. By analyzing the abovementioned genes using GSEA, we obtained 389 entries in the C2 gene set and plotted the GSEA plots. The results indicated that TRAIP was related to the proliferation (Figure S1 B-C), invasion (Figure S1 D-E), and metastasis (Figure S1 F-H) of tumors, as well as DNA replication (Figure S1 I-J), EMT (Figure S1 K-L), cell cycle (Figure S1 M-O), and Wnt/β-catenin pathway (Figure S1 P). Western blot was used to detect the relative TRAIP expression in CAL27, SCC15 and SCC9 cells (Figure S2A). CAL27 and SCC15 showing a high expression level of TRAIP were selected for silencing TRAIP expression (Figure S2B). SCC9 showed the lowest expression level of TRAIP, which was used to overexpress TRAIP (Figure S2C). In studying the effect of TRAIP on TSCC, the expression level of TRAIP was silenced or overexpressed using lentiviruses. Proliferation assay and colony formation assay showed that cells with TRAIP silencing proliferated slowly and conversely, the cells selected to overexpress TRAIP grew faster (P < 0.01, Fig. 2 A, B) compared with the NC group. Wound healing assay and Transwell assay revealed that TRAIP downregulation inhibited cell migration and invasion, but when TRAIP upregulated, the opposite applies (P < 0.05, Fig. 2 C, D). In exploring whether TRAIP influences the cell cycle progression in TSCC, groups with different TRAIP expression were involved. As shown in Fig. 2 , the percentage of cells increased in the G1 phase and decreased in the S phase in the shTRAIP group compared with the shNC group, and the trend was opposite in the TRAIP overexpressed group (P < 0.05, Fig. 2 E), indicating that TRAIP induces G1 cell cycle arrest in TSCC cells. TRAIP knockdown inhibits tumor growth and metastasis in vivo In conforming the effect of downregulated TRAIP on proliferation in vivo , CAL27 cells with shTRAIP and shNC were planted to nude mice subcutaneously and injected into the tail vein of nude mice separately. Six weeks later, the weight of mice of the two groups didn’t have significant difference (Fig. 3 A). The tumor size in the experimental group was significantly smaller than that in the NC group (100.90 \(\pm\) 31.95 \({mm}^{3}\) vs.745.80 \(\pm\) 153.84 \({mm}^{3}\) , P<0.05, Fig. 3 B, C). In addition, the tumor weight in the experimental group was significantly less than that in the shNC group (196.80 \(\pm\) 38.54mg vs. 1210.00 \(\pm\) 179.22mg, P < 0.05, Fig. 3 D). The in vivo bioluminescence imaging was used to detect metastasis in lung tissues. Three mice in the shTRAIP group had lung metastasis, whereas all five mice developed lung metastasis in the shNC group. The number of tumor foci detected in the shNC group was significantly more than that in the shTRAIP group (Fig. 3 E). Hematoxylin-eosin staining also confirmed this result (Fig. 3 F). These findings indicate that depleting TRAIP inhibits the proliferation and metastasis of TSCC cells in vivo. DDX39A may be the interacting protein of TRAIP In revealing the molecular mechanisms of TRAIP promoting TSCC progression, bioinformatics analysis, mass spectrometry and Co-IP were used. The flow chart is shown in figure S3. A total of 19,578 protein coding genes were obtained in patients with HNSC. The volcano maps are shown in Figure S4A. By taking the intersection of two differentially expressed genes and the results of mass spectrometry (table S2, table S3), and screening through the STRING database, 8 related genes were finally obtained (DNAJC9, RFC3, DDX18, CORO1C, ETF1, RFC4, DDX39A and PFDN2, Figure S4B-D). We found that RFC4 and DDX39A have higher relevance with TRAIP by analyzing the correlation between the abovementioned 8 genes and TRAIP (Figure S4E-M, table S4). Considering that the relationship between RFC4 and TSCC has been revealed[ 25 ], we selected DDX39A for the subsequent experiment. The relationship between TRAIP and DDX39A was confirmed by Co-IP (Fig. 4 A, B). Figure 4 A shows that DDX39A was one of the proteins that bind to TRAIP. Figure 4 B shows that TRAIP was also one of the proteins that bind to DDX39A. The DDX39A protein levels were decreased when TRAIP was knocked down in TSCC cell lines (Fig. 4 C). On the contrary, the DDX39A protein level increased when TRAIP was overexpressed (Fig. 4 D). When DDX39A was silenced or upregulated, the expression level of TRAIP was also downregulated or overexpressed (Fig. 4 E, F).In addition, truncated bodies mutually experiments show that the HELICc domain of DDX39A is the necessary structure for the interaction between DDX39A and TRAIP region (Fig. 4 G,H) TRAIP promotes TSCC cell proliferation and invasion by increasing DDX39A expression As shown in Fig. 4 , DDX39A knockdown inhibited cell proliferation (Fig. 5 A,B), cell cycle progression (Fig. 5 C-D, Figure S5A), migration, invasion (Fig. 5 E-J, Figure S5B) and caused G1 cell cycle arrest, and when DDX39A was overexpressed, the results were opposite. In determiningthe relationship between DDX39A and TRAIP in TSCC progression, rescue experiments were performed. DDX39A was overexpressed in TRAIP-knockdown cells and DDX39A was silenced in TRAIP overexpressed cells. Transwell assays indicated that DDX39A overexpression (partly) rescued the migration and invasion abilities in TRAIP-knockdown cells, and DDX39A silencing decreased the migration and invasion abilities caused by TRAIP overexpression (Fig. 5 K,L). These results suggested that TRAIP interacted with DDX39A during TSCC progression. TRAIP and DDX39A induces EMT in TSCC cells Western blot analysis showed that when TRAIP or DDX39A was suppressed, the protein levels of N-cadherin, Vimentin, Slug, Snail, MMP-2 and MMP-9 were decreased, and E-cadherin expression didn’t have obvious change (Fig. 6 A,-F). When TRAIP or DDX39A was upregulated, the expression level of N-cadherin, Vimentin, Slug, Snail, MMP-2 and MMP-9 was increased, and E-cadherin expression still didn’t remarkably change (Fig. 6 G-J). The overexpression of DDX39A might increase the expression level of EMT related proteins (except for E-cadherin) caused by TRAIP suppression (Fig. 6 K,L). In addition, the downregulation of DDX39A can decrease the expression level of EMT related proteins (except for E-cadherin) caused by TRAIP overexpression (Fig. 6 M,N). DDX39A and TRAIP regulated proliferation, migration and invasion via Wnt/β-catenin pathway in TSCC cells In exploring the mechanism of TRAIP and DDX39A in regulating cell progression in TSCC, we analyzed the protein levels of Wnt/β-catenin pathway. TRAIP or DDX39A silencing decreased the expression level of P-β-catenin, cyclinD1 and c-Myc, but β-catenin expression level didn’t significantly change (Fig. 7 A-F). Conversely, the expression level of P-β-catenin, cyclinD1 and c-Myc was increased after TRAIP or DDX39A overexpression, and β-catenin expression level still didn’t significantly change (Fig. 7 G-J). The overexpression of DDX39A might enhance the expression level of P-β-catenin, cyclinD1 and c-Myc caused by TRAIP suppression (Fig. 7 K,L). Moreover, the downregulation of DDX39A can diminish the expression level of related proteins caused by TRAIP overexpression (Fig. 7 M,N). The diagram was plotted using Biorender ( https://biorender.com/ , Fig. 8 ). Discussion At present, the main treatment of tongue carcinoma is surgery, and chemoradiation is also important in advanced stage patients[ 26 ]. However, these treatments damage patients’ appearance, cause psychosocial problems, and lead to functional defect, particularly dysphagia[ 27 , 28 ]. Some other severe complications are found in these therapies, which seriously influence the quality of life. Therefore, exploring ways at a molecular level is of great importance to improve patient prognosis. As a post-translational modification of proteins, ubiquitination plays an important role in many biological functions, such as proliferation, apoptosis and differentiation[ 29 , 30 ]. TRAIP is an E3 ubiquitin ligase, which has a RING finger motif and an extended coiled-coil domain[ 31 ]. Bioinformatics and previous studies have pointed that TRAIP is involved in cell progression. In addition, TRAIP plays an important role in regulating replisome stability and DNA interstrand cross-links repair pathway option[ 32 ]. Considering the mammalian replicative stress response and as a factor interacting with the proliferation cell nuclear antigen, TRAIP contributes to the recovery of impaired DNA replication forks[ 33 ]. TRAIP regulates mitotic process by regulating the spindle assembly checkpoint and it’s crucial to early mitotic process and arrangement of metaphase chromosomes[ 34 ]. Our research suggested that TRAIP is highly expressed in TSCC and closely related to the prognosis of patients. Therefore, TRAIP might promote the malignant behavior of TSCC. Our in vivo and in vitro experimental results also showed that TRAIP may stimulate the proliferation, migration and invasion of TSCC cells. Reports had suggested that TRAIP overexpression can increase the cell proliferation and metastatic ability in liver cancer, lung cancer, osteosarcoma and triple-negative breast cancer[ 10 – 12 ], these findings were consistent with our experimental results. However, TRAIP plays the opposite role in some tumors[ 35 , 36 ]. In choroidal melanoma, TRAIP overexpression weakens the ability of choroidal melanoma cells to proliferate, migrate and invade and inhibits EMT progression because of its ability to ubiquitinate Twist1, thereby mediating its proteasomal degradation[ 35 ]. Kong LR et al. showed that TRAIP dephosphorylates IĸB and impedes the nuclear translocation of RelA (p65), thereby repressing oncogenic nuclear factor kappa-B (NF-ĸB) signaling and inducing apoptosis[ 36 ]. This condition can often be explained by the fact that the same gene may play different roles in different types of tumors, such as DNA-binding protein inhibitor 4 (ID4). In prostate cancer, ID4 is epigenetically silenced and acts as a tumor suppressor[ 37 ]. However, ID4 is a potential oncogene in bladder cancer and colorectal cancer[ 38 ]. In addition, studies have shown that in some cases, the high expression of the tumor suppressor PTEN may lead to the proliferation and invasion of pre-B acute lymphoblastic leukemia cells, resulting in a poor prognosis[ 39 ]. These studies suggest that the role and impact of a gene may vary depending on factors such as cell type, tumor type and genetic environment. Our research also showed that silencing TRAIP induces G1 cell cycle arrest in TSCC cells, which consists with the role of TRAIP in foreskin keratinocyte[ 38 ]. After silencing TRAIP or DDX39A, the expression of cyclinD1 was decreased. The main function of cyclinD1 is to promote cell proliferation[ 40 ]. CyclinD1 binds to and activates the G1-phase unique cyclin-dependent kinase CDK4, which is phosphorylated by the G1 phase cycle inhibitor protein (Rb). Moreover, the phosphorylated Rb protein is dissociated from the E2F transcription factor to which it binds, and the E2F transcription factor initiates the transcription of genes in the living cell cycle, thereby promoting the cell cycle from the G1 phase to the S phase[ 41 , 42 ]. We hypothesized that TRAIP and DDX39A cause cell cycle arrest by inhibiting cyclinD1 expression. In this study, mass spectrometry, bioinformatics and Co-IP were used to identify the factor that plays a role with TRAIP in the progression of TSCC and DDX39A was selected. DDX39A belongs to the DEAD RNA helicase family, which is related to several cell processes, such as cells growth, migration, apoptosis, cytoskeletal rearrangement and RNA translocation[ 43 ]. Reports have suggested that DDX39A promotes cell growth and metastasis in hepatocellular carcinoma, melanoma and lung squamous cell carcinoma[ 44 ]. However, DDX39A inhibits the invasion ability of bladder cancer cells[ 45 ]. These studies suggest that DDX39A may play completely opposite roles in different tumors. By performing bioinformatics analysis, we found that DDX39A was highly expressed in TSCC tissue compared with normal tissue. We prove that DDX39A is the interacting protein of TRAIP, and HELICc domain of DDX39A is the key to interact with TRAIP.The interaction of TRAIP and DDX39A can regulate the proliferation, migration, invasion abilities and cell cycle progression in TSCC. Furthermore, our results showed that DDX39A and TRAIP enhanced TSCC migration and invasion via EMT pathway and Wnt/β-catenin signaling. Reports have indicated that DDX39A was highly expressed in several carcinomas, which can promote tumors progression, for instance, renal clear cell carcinoma, melanoma, hepatocellular carcinoma and breast cancer[ 46 , 47 ]. These studies were in accordance with our findings. DDX39A was also related to chemoresistance in ER positive breast cancer and human pancreatic cancer[ 47 , 48 ]. This protein may be an important immune checkpoint for it can cause tumor immune escape in renal clear cell carcinoma[ 46 ]. Therefore, the interaction of TRAIP and DDX39A is of great importance in TSCC progression. The Wnt/β-catenin pathway is crucial to cell proliferation and metastasis, and during the activation of Wnt/β-catenin pathway, β-catenin accumulates in the cytoplasm, then enters the nucleus and interacts with T-cell factor/lymphoid enhancer factor (TCF/LEF), activating Wnt target genes, leading to tumorigenesis and metastasis[ 49 ]. EMT is a key process of cancer cell metastasis, during which epithelial cells acquired the characteristics of mesenchymal cells, enhanced cell motility and increased migration ability[ 50 ]. Research showed that DDX39A promotes hepatocellular carcinoma growth and metastasis by activating Wnt/β-catenin pathway[ 44 ]. However, studies related to DDX39A and EMT have not been reported. Our research indicated that TRAIP and DDX39A could regulate cell progression through EMT and Wnt/β-catenin pathway. Up to now, this study is the first to investigate (1) TRAIP expression in TSCC and its relationship with clinicopathological characteristics of TSCC patients, (2) the effect of TRAIP and DDX39A on progression of TSCC cells, (3) the interaction of TRAIP and DDX39A in TSCC progression, (4) the mechanism by which the two factors regulate tumor malignant behaviors. Our research indicates that TRAIP and DDX39A may be potential treatment targets in TSCC. Declarations Acknowledgements Not applicable. Funding This research was supported by the Natural Science Foundation of Shandong Province (ZR2022MH206), the National Natural Science Foundation of China (No.81672606), and Beijing Jingjian Pathology Development Foundation (JJlXA2022-008). Availability of data and materials All data from this study are available from the corresponding author. Author contributions CW was responsible for the conception and design. PW, LL and CG contributed to the experimental performance. LS, LC, HQ and YZ were responsible for data analysis. PW, CW and XX were responsible for manuscript writing and revision. Ethics approval and consent to participate The research protocol was approved by the Medical Ethical Committee of the Affiliated Hospital of Qingdao University (registration no. QYFY WZLL 27524) and Qingdao University Laboratory Animal Welfare Ethics Committee (registration no. 20210420BALB/Cnude100615001). All patients or their guardians were given and accepted informed consent. Patient consent for publication All patients or their guardians gave consent to publication. Declaration of interests The authors declared no conflict of interest. References Warnakulasuriya S, Kerr AR. Oral Cancer Screening: Past, Present, and Future. J Dent Res. 2021;100(12):1313–20. Pillai J, et al. A systematic review of proteomic biomarkers in oral squamous cell cancer. World J Surg Oncol. 2021;19(1):315. Lenze NR, et al. Age and risk of recurrence in oral tongue squamous cell carcinoma: Systematic review. Head Neck. 2020;42(12):3755–68. Zhang K, et al. LUCAT1 as an oncogene in tongue squamous cell carcinoma by targeting miR-375 expression. J Cell Mol Med. 2021;25(10):4543–50. Wikner J, et al. Squamous cell carcinoma of the oral cavity and circulating tumour cells. World J Clin Oncol. 2014;5(2):114–24. Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8(9):11884–94. Bonomo P, et al. Quality Assessment in Supportive Care in Head and Neck Cancer. Front Oncol. 2019;9:926. Rinkel RN, et al. Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI. Eur Arch Otorhinolaryngol. 2016;273(7):1849–55. Chapard C, Hohl D, Huber M. The role of the TRAF-interacting protein in proliferation and differentiation. Exp Dermatol. 2012;21(5):321–6. Guo Z, et al. TRAIP promotes malignant behaviors and correlates with poor prognosis in liver cancer. Biomed Pharmacother. 2020;124:109857. Liu Y, et al. LncRNA SLC7A11-AS1 Contributes to Lung Cancer Progression Through Facilitating TRAIP Expression by Inhibiting miR-4775. Onco Targets Ther. 2020;13:6295–302. Li M, et al. TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation. Cell Death Dis. 2021;12(8):767. Zheng Y, et al. Silencing TRAIP suppresses cell proliferation and migration/invasion of triple negative breast cancer via RB-E2F signaling and EMT. Cancer Gene Ther. 2023;30(1):74–84. Park ES, et al. Early embryonic lethality caused by targeted disruption of the TRAF-interacting protein (TRIP) gene. Biochem Biophys Res Commun. 2007;363(4):971–7. Regamey A, et al. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med. 2003;198(12):1959–64. Chen C, Huang H, Wu CH. Protein Bioinformatics Databases and Resources. Methods Mol Biol. 2017;1558:3–39. Reyes M et al. Wnt/β-Catenin Signaling in Oral Carcinogenesis. Int J Mol Sci, 2020. 21(13). Vivian J, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314–6. Zhuang Z, et al. Down-Regulation of Long Non-Coding RNA TINCR Induces Cell Dedifferentiation and Predicts Progression in Oral Squamous Cell Carcinoma. Front Oncol. 2020;10:624752. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res, 2002. 30(1): pp. 207 – 10. Robin X, et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. Wu T, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2(3):100141. Wang C, et al. Silencing of KIF3B Suppresses Breast Cancer Progression by Regulating EMT and Wnt/β-Catenin Signaling. Front Oncol. 2020;10:597464. Zhang J, Wang L, Xie X. RFC4 promotes the progression and growth of Oral Tongue squamous cell carcinoma in vivo and vitro. J Clin Lab Anal. 2021;35(5):e23761. Gonzalez M, Riera March A. Tongue Cancer , in StatPearls . 2021, StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.: Treasure Island (FL). Cohen Goldemberg D et al. Tongue cancer epidemiology in Brazil: incidence, morbidity and mortality. 2018. 40(8): pp. 1834–1844. Huang ZS, et al. Dysphagia in Tongue Cancer Patients Before and After Surgery. J Oral Maxillofac Surg. 2016;74(10):2067–72. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from structures to functions. Nat Rev Mol Cell Biol. 2009;10(10):659–71. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 2005;6(8):599–609. Lee SY, Lee SY, Choi Y. TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J Exp Med. 1997;185(7):1275–85. Wu RA, et al. TRAIP is a master regulator of DNA interstrand crosslink repair. Nature. 2019;567(7747):267–72. Feng W, et al. TRAIP regulates replication fork recovery and progression via PCNA. Cell Discov. 2016;2:16016. Chapard C, et al. TRAIP is a regulator of the spindle assembly checkpoint. J Cell Sci. 2014;127(Pt 24):5149–56. Wei C, et al. TRIP suppresses cell proliferation and invasion in choroidal melanoma via promoting the proteasomal degradation of Twist1. FEBS Lett. 2020;594(19):3170–81. Kong LR et al. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. Nat Commun, 2020. 11(1): p. 2086. Komaragiri SK, et al. ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells. Biochem Biophys Res Commun. 2016;478(1):60–6. Ou D, et al. miR-340-5p affects oral squamous cell carcinoma (OSCC) cells proliferation and invasion by targeting endoplasmic reticulum stress proteins. Eur J Pharmacol. 2022;920:174820. Shojaee S, et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016;22(4):379–87. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–7. Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22(6):356–72. Narita M, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113(6):703–16. Chan CH, et al. DNA Damage, Liver Injury, and Tumorigenesis: Consequences of DDX3X Loss. Mol Cancer Res. 2019;17(2):555–66. Zhang T, et al. DDX39 promotes hepatocellular carcinoma growth and metastasis through activating Wnt/β-catenin pathway. Cell Death Dis. 2018;9(6):675. Kato M, et al. DDX39 acts as a suppressor of invasion for bladder cancer. Cancer Sci. 2012;103(7):1363–9. Bao Y, et al. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma. Int J Biol Sci. 2021;17(12):3158–72. Wang X, et al. DEAD-box RNA Helicase 39 Promotes Invasiveness and Chemoresistance of ER-positive Breast Cancer. J Cancer. 2020;11(7):1846–58. Kuramitsu Y, et al. Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells. Anticancer Res. 2013;33(8):3133–6. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006;281(32):22429–33. Nieto MA, et al. EMT: 2016. Cell. 2016;166(1):21–45. Tables Table 1 is available in the Supplementary Files section. Additional Declarations No competing interests reported. Supplementary Files Table1.zip supplement.zip Cite Share Download PDF Status: Published Journal Publication published 02 Dec, 2024 Read the published version in BMC Cancer → Version 1 posted Editorial decision: Revision requested 24 Apr, 2024 Editor assigned by journal 24 Apr, 2024 Submission checks completed at journal 18 Apr, 2024 First submitted to journal 14 Apr, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4266683","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":292584044,"identity":"34b3f0e4-bb4b-4084-a6ab-1f2387c92f1f","order_by":0,"name":"Litong Liu","email":"","orcid":"","institution":"Qingdao University","correspondingAuthor":false,"prefix":"","firstName":"Litong","middleName":"","lastName":"Liu","suffix":""},{"id":292584045,"identity":"16e112ad-2dfd-4145-9932-513108d69a99","order_by":1,"name":"ping Wang","email":"","orcid":"","institution":"Linyi People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"ping","middleName":"","lastName":"Wang","suffix":""},{"id":292584046,"identity":"f66f4ff3-bf70-499a-bbeb-2793612569ef","order_by":2,"name":"cheng Guo","email":"","orcid":"","institution":"Qingdao University","correspondingAuthor":false,"prefix":"","firstName":"cheng","middleName":"","lastName":"Guo","suffix":""},{"id":292584047,"identity":"caccfc9d-c401-4509-97a7-a5634ebe2e9a","order_by":3,"name":"li Song","email":"","orcid":"","institution":"Qingdao University","correspondingAuthor":false,"prefix":"","firstName":"li","middleName":"","lastName":"Song","suffix":""},{"id":292584048,"identity":"dccc7484-3338-49cd-9977-c0b849259d15","order_by":4,"name":"lifang Chen","email":"","orcid":"","institution":"the Affiliated Hospital of Qingdao University","correspondingAuthor":false,"prefix":"","firstName":"lifang","middleName":"","lastName":"Chen","suffix":""},{"id":292584049,"identity":"75ad8ec9-6369-4a76-ab58-1eb52fee143a","order_by":5,"name":"hongbin Qi","email":"","orcid":"","institution":"the Affiliated Hospital of Qingdao University","correspondingAuthor":false,"prefix":"","firstName":"hongbin","middleName":"","lastName":"Qi","suffix":""},{"id":292584050,"identity":"148815da-6899-4f17-b5b3-e29cd58f4c39","order_by":6,"name":"Yangyang Zheng","email":"","orcid":"","institution":"Qingdao University","correspondingAuthor":false,"prefix":"","firstName":"Yangyang","middleName":"","lastName":"Zheng","suffix":""},{"id":292584051,"identity":"2a3524b3-b1f5-48b1-a378-5674bd9c03aa","order_by":7,"name":"xiaoming Xing","email":"","orcid":"","institution":"the Affiliated Hospital of Qingdao University","correspondingAuthor":false,"prefix":"","firstName":"xiaoming","middleName":"","lastName":"Xing","suffix":""},{"id":292584052,"identity":"649eafdd-1ad9-4801-adef-52e9cada6157","order_by":8,"name":"Chengqin Wang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAvUlEQVRIiWNgGAWjYJCCAx//2cixsTcfIFoH48MZbGnGfDzHEojWwmzMw3Y4cZ5EjgJx6g2OH94mOYPncHobQw4Dw4+KbURoOZNWJvFBIj23jeHsAcaeM7cJazG7wWMmOcPAOreNsS+BmbGNSC3SPAnM6WzMPAZEazE25jngnMDGRqwW+zNphQ9nNqQZtvGwJRwkyi+S7Yc3HPjYYCMvP//xwQc/KojQAgQGcNYBotSjaBkFo2AUjIJRgBUAABerO8iSgmJDAAAAAElFTkSuQmCC","orcid":"","institution":"Qingdao University","correspondingAuthor":true,"prefix":"","firstName":"Chengqin","middleName":"","lastName":"Wang","suffix":""}],"badges":[],"createdAt":"2024-04-15 01:59:18","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4266683/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4266683/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12885-024-13130-8","type":"published","date":"2024-12-02T15:57:03+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":55324966,"identity":"2744dc09-e496-41a6-a5f1-9b8cd604ac14","added_by":"auto","created_at":"2024-04-25 16:55:25","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":324821,"visible":true,"origin":"","legend":"\u003cp\u003eThe expression level of TRAIP is upregulated in TSCC. (A) The level of TRAIP expression in different human normal tissues. (B) TRAIP levels in unpaired HNSC tissues and normal tissues in TCGA. (C) TRAIP levels in paired HNSC tissues and normal tissues in TCGA. (D) TRAIP levels in paired HNSC tissues and normal tissues in GSE. (E) ROC for TRAIP to diagnose HNSC. (F) TRAIP protein expression levels in TSCC were higher than that in normal tissues. T: tumor, N: normal tissue.\u003cstrong\u003e \u003c/strong\u003e(G) Representative IHC images of TRAIP expression. *P\u0026lt; 0.05, **P\u0026lt; 0.01, ***P\u0026lt; 0.001.\u003c/p\u003e","description":"","filename":"figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/3b13548a6343e51a21b59dc7.png"},{"id":55323987,"identity":"5860c7da-f8dc-490c-8f61-5a99b696bbe3","added_by":"auto","created_at":"2024-04-25 16:47:25","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":2629535,"visible":true,"origin":"","legend":"\u003cp\u003eTRAIP promotes TSCC cell proliferation, migration and invasion \u003cem\u003ein vitro\u003c/em\u003e. Cell viability was tested using proliferation assay (A). Cell proliferation ability was detected using colony formation assay (B). Wound healing assay (C) and transwell assay (D) were used to detect the migration and invasion abilities of TSCC cell. (E) The distribution of cell phase in TSCC cell lines after TRAIP was silenced or overexpressed. Data are shown as mean±SD (n=3). *P\u0026lt; 0.05, **P\u0026lt; 0.01, ***P\u0026lt; 0.001.\u003c/p\u003e","description":"","filename":"figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/fe161c6abb9def8c45435408.jpg"},{"id":55324969,"identity":"895e0a48-cdb9-4b6b-8e76-84f3747c31e2","added_by":"auto","created_at":"2024-04-25 16:55:26","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":558480,"visible":true,"origin":"","legend":"\u003cp\u003eTRAIP knockdown inhibited TSCC cell growth and metastasis \u003cem\u003ein vivo\u003c/em\u003e. (A) The weight of mice. (B) Dissected tumors generated by TRAIP knockdown or negative control CAL27 cell (n=5). (C, D) The growth curve (C) and weights of xenograft tumors (D). (E) The metastatic nodules of nude mice lungs after tail vein injection of TRAIP knockdown or negative control CAL27 cell. (F) Representative HE images of lung tissues after tail vein injection (left × 200; right × 400; upper: shTRAIP group; lower: shNC group). *P\u0026lt; 0.05.\u003c/p\u003e","description":"","filename":"figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/352f5335fdb04976d0299aeb.png"},{"id":55324967,"identity":"18daf2e6-83a6-4e17-aaff-186842dbaa0f","added_by":"auto","created_at":"2024-04-25 16:55:25","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":256507,"visible":true,"origin":"","legend":"\u003cp\u003eTRAIP interacts with DDX39A in TSCC cells. (A, B) Whole-cell lysates of CAL27, SCC15 and SCC9 cells were used in Co-IP with IgG (control) and anti-TRAIP or anti-DDX39A antibodies. (C-F) Western blot analysis was used to measure the expression of TRAIP and DDX39A in these two factors silenced or overexpressed cells. (G) Schematic of DDX39A domains. (H) Co-immunoprecipitation analysis of the interaction of Flag-TRAIP and WT or truncated MYC-DDX39A.\u003c/p\u003e","description":"","filename":"figure4.png","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/dd09bed7afbde8ac4ce631bc.png"},{"id":55323990,"identity":"fa2bed46-fed4-46cb-b043-33538399ded5","added_by":"auto","created_at":"2024-04-25 16:47:25","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":456596,"visible":true,"origin":"","legend":"\u003cp\u003eDDX39A promotes TSCC cell proliferation and migration \u003cem\u003ein vitro\u003c/em\u003e. Cell growth ability was determined using proliferation assay (A) and colony formation assay (B), (C) The distribution of cell phase after DDX39A was silenced or overexpressed. The migration abilities were measured using wound healing assay (D).\u003cstrong\u003e \u003c/strong\u003eDDX39A promotes TSCC cell migration and invasion\u003cem\u003e in vitro\u003c/em\u003e. The migration and invasion abilities were measured using Transwell assay (A, B) *P\u0026lt; 0.05, **P\u0026lt; 0.01, ***P\u0026lt; 0.001.\u003c/p\u003e","description":"","filename":"figure5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/0ff1f5a4002366e7b353e989.jpg"},{"id":55323993,"identity":"0fc72360-d8e7-4a93-b048-99148cba64be","added_by":"auto","created_at":"2024-04-25 16:47:25","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":478428,"visible":true,"origin":"","legend":"\u003cp\u003eTRAIP promotes TSCC cell migration and invasion by EMT. Western blot analysis was used to determine the protein levels of E-cadherin, N-cadherin, Vimentin, Slug, Snail, MMP2, MMP9 after TRAIP or DDX39A was silenced (A-F). TRAIP promotes TSCC cell migration and invasion by EMT. Western blot analysis was used to determine the protein levels of E-cadherin, N-cadherin, Vimentin, Slug, Snail, MMP2, MMP9 after TRAIP or DDX39A was overexpressed (G-J). CAL27 and SCC9 cells were transfected with lentiviruses. Cells were used to detect the EMT relative proteins expression (K-N).\u003c/p\u003e","description":"","filename":"figure6.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/eb4099c4b349313a4cec37fd.jpg"},{"id":55324968,"identity":"8ae0cc54-3ea3-4f76-8734-4bf8e1f13804","added_by":"auto","created_at":"2024-04-25 16:55:25","extension":"jpg","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":394310,"visible":true,"origin":"","legend":"\u003cp\u003eTRAIP and DDX39A activate Wnt/β-catenin pathway in TSCC cells. Western blot analysis of Wnt/β-catenin pathway relative proteins after TRAIP or DDX39A knockdown (A-F). TRAIP and DDX39A activate Wnt/β-catenin pathway in TSCC cells. Western blot analysis of Wnt/β-catenin pathway relative proteins after TRAIP or DDX39A overexpressed (G-J). CAL27 and SCC9 cells were transfected with lentiviruses. Cells were used to detect the Wnt/β-catenin pathway relative proteins expression (K-N).\u003c/p\u003e","description":"","filename":"figure7.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/5a507a4d68299d54ab43e4c4.jpg"},{"id":55323995,"identity":"2c0b8502-b753-4024-94af-40423723368b","added_by":"auto","created_at":"2024-04-25 16:47:26","extension":"jpg","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":812916,"visible":true,"origin":"","legend":"\u003cp\u003eThe schematic diagram of TRAIP regulates TSCC cells proliferation, migration and invasion by interacting with DDX39A via Wnt/β-catenin pathway. By BioRender.\u003c/p\u003e","description":"","filename":"figure8.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/5de69503b97a60198d2fa3ee.jpg"},{"id":70964621,"identity":"54a45422-b626-4926-aa35-b8c087120afe","added_by":"auto","created_at":"2024-12-09 16:12:01","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":6558529,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/662ef8a0-5a76-4343-a1f6-ec28d3087d8f.pdf"},{"id":55323988,"identity":"60ab79b7-e8e5-40bd-8eed-6e48bc2c5747","added_by":"auto","created_at":"2024-04-25 16:47:25","extension":"zip","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":16223,"visible":true,"origin":"","legend":"","description":"","filename":"Table1.zip","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/0167e7543a5bb755fc217a5c.zip"},{"id":55323996,"identity":"2480ee34-54f5-48fb-9bf7-81f3cd5bb85c","added_by":"auto","created_at":"2024-04-25 16:47:26","extension":"zip","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":3996203,"visible":true,"origin":"","legend":"","description":"","filename":"supplement.zip","url":"https://assets-eu.researchsquare.com/files/rs-4266683/v1/af09d5015c9c6401fc1ff951.zip"}],"financialInterests":"No competing interests reported.","formattedTitle":"TRAIP enhances progression of tongue squamous cell carcinoma through EMT and Wnt/β-catenin signaling by interacting with DDX39A","fulltext":[{"header":"Introduction","content":"\u003cp\u003eOral cancer is a highly prevalent cancer worldwide, and more than 90% of the cases are squamous cell carcinoma[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e], which is the most common malignant tumor of the head and neck[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Tongue cancer is a branch of head and neck cancer. The incidence rate of tongue squamous cell carcinoma (TSCC) gradually increases, especially in young patients[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Many cases were diagnosed in advanced stage because of lack of symptoms[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Early regional lymph nodes metastasis and unsatisfactory chemotherapeutic treatment are also related to high mortality[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Despite various treatments, the long-term prognosis of TSCC is poor, and the 5 year survival rate is about 50%[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. The survivors also have many severe disabilities, such as swallowing and speech disorders[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Therefore, finding effective targeted therapeutic molecules to TSCC is urgently needed.\u003c/p\u003e \u003cp\u003eTumor necrosis factor receptor-associated factor interacting protein (TRAIP) is a ring-dependent E3 ubiquitin ligase, it\u0026rsquo;s a 53-kDa protein, with a 55-aminoacid-long ring domain at its N-terminal end, a putative coiled-coil domain and a leucine zipper region[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Through bioinformatic analysis, we found that the expression of TRAIP in head and neck squamous cell carcinoma (HNSC) was remarkably higher than that of normal tissues. Previous reports have pointed that TRAIP involves cell progression of many tumors[\u003cspan additionalcitationids=\"CR11 CR12\" citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. TRAIP is highly expressed in liver cancer, and such overexpression encouraged malignant behavior of liver cancer cells[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In a previous study, TRAIP defective homozygous mouse died in the early embryonic stage because of proliferation defect and excessive cell death[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. The overexpression of TRAIP enhanced the proliferation, metastasis, and invasion ability of lung cancer cells[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Interacting with CYLD, TRAIP serves as a tumor suppressor in basal cell carcinoma[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. TRAIP improves the invasion and proliferation abilities of osteosarcoma and triple negative breast cancer[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Therefore, we hypothesize that TRAIP may be a new target in TSCC. However, no research has been conducted on the relationship between TRAIP and TSCC. Bioinformatics is a field that uses mathematics, information technology, statistics and computer science to research biological questions. At present, several bioinformatics databases can be used to analyze proteins sequence, structure and functions[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eTherefore, we used bioinformatics to analyze the relationship between TRAIP and TSCC, and to verify the results. Our study found that TRAIP regulated the proliferation and invasion of TSCC cells by interacting with DDX39A. The Wnt signaling pathway and epithelial-mesenchymal transition (EMT) play important roles in the progression of oral cancer[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. We further investigated the relationship among TRAIP, DDX39A, Wnt/β-catenin and EMT. These results indicate that TRAIP may be a new potential target in TSCC treatment.\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eTRAIP gene expression analysis\u003c/h2\u003e \u003cp\u003eWe obtained the expression of TRAIP in different normal tissues from the Human Protein Atlas (HPA) database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.proteinatlas.org/\u003c/span\u003e\u003cspan address=\"https://www.proteinatlas.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e)[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Unpaired and paired HNSC data from TCGA database joint GTEx database and one datasets (GSE160042[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]) containing TSCC tissue and normal tissue samples from Gene Expression Omnibus (GEO) database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ncbi.nlm.nih.gov/geo/\u003c/span\u003e\u003cspan address=\"https://www.ncbi.nlm.nih.gov/geo/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e)[\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e] were analyzed and boxplots were drawn. The pROC[\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e] package and ggplot2 package were used for plotting ROC curve. We obtained the variation information of TRAIP in patients with HNSC from TCGA database by using cBioPortal (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.cbioportal.org/\u003c/span\u003e\u003cspan address=\"https://www.cbioportal.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eEnrichment analysis\u003c/h2\u003e \u003cp\u003eTRAIP expression levels were grouped (transcripts per million (TPM) data, Low TRAIP: 0%-50%. High TRAIP: 50%-100%) and differential analysis was performed using DESeq2[\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e] package to obtain differential genes, screen protein coding genes and draw volcano maps. GSEA was analyzed by using clusterProfiler[\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e] package (the number of calculations was 10000, and the gene set ranged from 10 to 1000, p.adj\u0026thinsp;\u0026lt;\u0026thinsp;0.05, FDR\u0026thinsp;\u0026lt;\u0026thinsp;0.2, |NES| \u0026gt; 1.8, species: homo sapiens).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eTRAIP downstream molecular screening\u003c/h2\u003e \u003cp\u003eThrough the same processing as before, the mass spectrometry, HNSC-related differential genes and TRAIP-related differential genes were intersected to obtain the genes that were simultaneously related to HNSC and TRAIP and were screened in the mass spectrometry. TRAIP related proteins were obtained by co-immunoprecipitation (CO-IP), and then the samples were used for mass spectrometry test. The mass spectrometry was finished by Shanghai OE Biotechnology Company (Shanghai, China). The results are shown in supplementary material (Table S3 and S4). We selected several genes related to cancer cell proliferation and invasion from the mass spectrometry results. These genes were input into the STRING (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://string-db.org/\u003c/span\u003e\u003cspan address=\"https://string-db.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) for molecular interaction analysis. The heatmap and scatter plot of the correlation between these genes and TRAIP were drawn by ggplot2. These results suggested that TRAIP may interact with other genes in TSCC, which need further verification.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eSpecimens and cell culture\u003c/h2\u003e \u003cp\u003eSixty-five TSCC tissues, corresponding adjacent normal tissues and related clinical characteristics (Table\u0026nbsp;1) were collected at the Affiliated Hospital of Qingdao University between 2014 and 2016. Specimens from cancer tissue and adjacent normal tissue were obtained during surgery and were immediately dipped in 10% formalin for immunohistochemistry (IHC). No patients received radiotherapy or chemotherapy before surgery. Nine pairs of fresh cancer and adjacent tissue collected at the Affiliated Hospital of Qingdao University were immediately frozen in liquid nitrogen and stored for protein analysis. All patients have signed the informed consent document. The study was approved by the Institutional Medical Ethics Committee of the Qingdao University Affiliated Hospital.\u003c/p\u003e \u003cp\u003eHuman TSCC cell lines were obtained from Culture Collection of Chinese Academy of Science (Shanghai, China). CAL27 is known to be an adenosquamous cell carcinoma, in the following decades after CAL 27 cell line was established, it has been widely used to build OSCC models for studies in \u003cem\u003evitro\u003c/em\u003e and in \u003cem\u003evivo\u003c/em\u003e and thus regarded as a representative cell line for OSCC studying. All cell lines were tested and characterized using STR profiles and were regularly evaluated for mycoplasma. The cells were cultured in Dulbecco modified Eagle\u0026rsquo;s medium (DMEM, Gibco, New York, USA) containing 10% fetal bovine serum (Transgen Biotech, Beijing, China), penicillin (100 units/ml) and streptomycin(100mg/ml) at 37℃ in 5% CO\u003csub\u003e2\u003c/sub\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eImmunohistochemistry (IHC)\u003c/h2\u003e \u003cp\u003eThe operating steps of IHC staining were introduced previously[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. After deparaffinization and hydration, the slides were inactivated endogenous peroxidase by using 3% hydrogen peroxide and heat-pretreated in ethylene diamine tetraacetic acid (pH 8.0) for 5 min by using a microwave oven. Then the anti-TRAIP antibody (Abcam, United Kingdom, dilution at 1:300, 4\u0026deg;C, overnight) and the sheep anti-rabbit antibody (Abcam, dilution at 1:100, 37\u0026deg;C, 30min) were incubated. Sections thickness was set at 4\u0026micro;m, stained with diaminobenzidine (DAB) and counterstained with hematoxylin. Phosphate-buffered saline (PBS) acts as negative control (NC). The results of IHC staining were scored in accordance with staining intensity and percentage of positive tumor cells. The total score contains the staining intensity (0, none; 1, weak; 2, intermediate; 3, strong) and tumor cell positive ratio (0, none; 1, \u0026lt;\u0026thinsp;1/100; 2, 1/100-1/10; 3, 1/10\u0026thinsp;\u0026minus;\u0026thinsp;1/3; 4, 1/3\u0026thinsp;\u0026minus;\u0026thinsp;2/3; 5, \u0026gt;\u0026thinsp;2/3).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eCell transfection\u003c/h2\u003e \u003cp\u003eLentiviral-transduced shRNA interference was performed to inhibit TRAIP and DDX39A expression. The lentivirus was purchased from GenePharma (GenePharma, China) and Genechem (Genechem, China). CAL27 and SCC15 cells were transfected with shTRAIP and shDDX39A, and SCC9 was transfected with oeTRAIP and oeDDX39A. CAL27 and SCC15 cells with TRAIP and DDX39A suppressed contained shTRAIP and shDDX39A, SCC9 with TRAIP and DDX39A overexpressed contained oeTRAIP and oeDDX39A, the control group was transfected with NC RNA. 4\u0026times;10\u003csup\u003e4\u003c/sup\u003e cells were cultured in 6-well plates with 10% fetal bovine serum until 70%-80% of the plates\u0026rsquo; bottom was carpeted. After transfection with lentivirus in DMEM for 24h, the culture medium was replaced with complete growth medium with 10% fetal bovine serum. Cells were cultured in medium containing puromycin after 48h for follow-up experiments. All relative sequences are listed in Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eWestern blot\u003c/h2\u003e \u003cp\u003eAfter covering the bottom surface of T25 culture flask, about 5\u0026times;10\u003csup\u003e6\u003c/sup\u003e cells were used to extract proteins. Western blot assay was performed as described previously[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The following antibodies were used in this study: anti-TRAIP (Proteintech Group, Inc., Chicago, USA, dilution at 1:1000), anti-β-actin (Proteintech Group, Inc., Chicago, USA, dilution at 1:4000), anti-DDX39A, anti-E-cadherin, anti-N-cadherin, anti-Vimentin, anti-Slug, anti-Snail, anti-MMP2, anti-MMP9, anti-P-β-catenin, anti-β-catenin, anti-c-Myc, anti-cyclinD1 (Abclonal Technology, China, dilution at 1:1000). The stripe gray value of the target protein was measured using Image J and divided by the gray value of the reference protein for normalization. Then the obtained values were homogenized with reference to the control group data, and the expression trend value can be obtained. CAL27, SCC15 and SCC9 were used for western blot assay.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eCo-IP\u003c/h2\u003e \u003cp\u003eAfter covering the bottom surface of the petri dish with a diameter of 10cm, about 10\u003csup\u003e7\u003c/sup\u003e cells were disposed accordance with the Co-IP kit instructions (Takara Biotechnology, Japan). Then, 10\u0026micro;l of 5\u0026times; loading buffer was added into the protein, and the mixture was boiled for 15 min. The protein-protein complexes were later subjected to western blot and IgG was used as a NC. CAL27, SCC15 and SCC9 were used for Co-IP experiment.\u003c/p\u003e \u003cp\u003e \u003cb\u003eProliferation assay\u003c/b\u003e A total of 2000 cells in 100\u0026micro;l complete growth medium were seeded in 96-well plates and cultured separately for 1,2,3,4,5 days in an incubator before 10\u0026micro;l of CCK-8 solution was added in each well for 1h. The optical density value was detected at 450nm by using a microplate reader. Each experiment was repeated three times. CAL27, SCC15 and SCC9 were used for proliferation assay.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eMigration and invasion assays\u003c/h2\u003e \u003cp\u003eIn testing the migration ability of CAL27, SCC15 and SCC9, 5\u0026times;\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\({10}^{5}\\)\u003c/span\u003e\u003c/span\u003e cells in 100\u0026micro;l of serum-free medium were added in upper Transwell chambers. The lower chamber was loaded with 500\u0026micro;l of culture medium containing 30% fetal bovine serum. After incubating CAL27, SCC15 and SCC9 for 21, 15, and 17h respectively, a cotton swab was used to wipe off cells in the upper chamber. The lower surface of Transwell chamber was immerged in 4% paraformaldehyde for 25 min and then dyed with 0.1% crystal violet.\u003c/p\u003e \u003cp\u003eIn completing cells\u0026rsquo; invasion assay, the inner surface of the Transwell chamber was laid with 100\u0026micro;l of diluted Matrigel (Corning, USA) and placed in an incubator for 1h. The 5\u0026times;\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\({10}^{5}\\)\u003c/span\u003e\u003c/span\u003e cells were added into the upper Transwell chamber and incubated for 27, 22 and 23h for CAL27, SCC15 and SCC9, respectively. The rest of the steps were basically the same as describedpreviously. The total number of cells on the lower surface counted by Image J was regarded as the number of migrated cells.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eColony formation assays\u003c/h2\u003e \u003cp\u003eTSCC cells were digested by pancreatin and counted by using a cell counting plate. The 1\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\times {10}^{3}\\)\u003c/span\u003e\u003c/span\u003e cells on a single-cell suspension condition in a 2ml culture medium were inoculated in 6-well plates. After being incubated for 14 days, the inner surface of the plate was immerged in 4% paraformaldehyde for 25 min and then dyed with 0.1% crystal violet. The colony number was calculated. CAL27, SCC15 and SCC9 were used for colony formation assays.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eWound healing assays\u003c/h2\u003e \u003cp\u003eTSCC cells were seeded in 6-well plates and incubated until cells covered the bottom surface of plates. The inner surface cells were scratched using 200\u0026micro;l pipette tip to create straight lines and then washed 3 times with PBS to eliminate detached cells. Then the cells were cultured in incubator with serum-free medium for 24h. Wound area pictures of 0h and 24h were taken. The migration ability of cells is evaluated by measuring the area changes of the injured area using Image J in accordance with the following: scratch closure rate (%) = (injured area of 0h - injured area of 24h) / injured area of 0h \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\times 100\\text{\\%}\\)\u003c/span\u003e\u003c/span\u003e. CAL27, SCC15 and SCC9 were used for wound healing assays. The experiment was repeated 3 times.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eTumor xenografts in nude mice\u003c/h2\u003e \u003cp\u003eNude mouse tumorigenesis experiment is a common experiment to study the biological characteristics of human tumors and tumor treatment. And the transplanted nude mouse tumor model has the advantages of high tumor formation rate, good uniformity, and could more accurately reflect the biological characteristics of the tumor cells. Six-week-old BALB/c nude mice were used for subcutaneous tumor implantation experiments. The 1\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\times {10}^{6}\\)\u003c/span\u003e\u003c/span\u003eCAL27 cells of the NC group and experimental group resuspended in 100\u0026micro;l of PBS (phosphate buffer) and mixed with equal volume of Matrigel (8.1mg/ml) were implanted to the right flank of each nude mouse subcutaneously for 6 weeks. The tumor was measured using a ruler each week. The tumor volume didn\u0026rsquo;t reach 1500\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\({mm}^{3}\\)\u003c/span\u003e\u003c/span\u003e before the deadline of 6 weeks in accordance with the following formula: volume\u0026thinsp;=\u0026thinsp;1/2\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\times\\)\u003c/span\u003e\u003c/span\u003elength\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\times\\)\u003c/span\u003e\u003c/span\u003e width\u003csup\u003e2\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eFor the lung metastasis model, 1\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\times {10}^{6}\\)\u003c/span\u003e\u003c/span\u003e cells were injected into the tail vein of nude mice. Six weeks later, mice were euthanized by cervical dislocation and the lung tissues were anatomized and analyzed by HE staining. The research protocol was approved by the Qingdao University Laboratory Animal Welfare Ethics Committee.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eCell cycle analysis\u003c/h2\u003e \u003cp\u003eCells were seeded in 6-well plates for 24h and then collected to 15ml centrifugal tubes. After centrifugation at 1000g and 4℃ for 5 min, cells were washed by precooled PBS and centrifugated at the abovementioned condition. Cells were resuspended with 70% ethanol and placed in refrigerator at 4℃ for at least 2h. After being resuspended with 250\u0026micro;l of binding buffer and adjusted to the concentration of 1\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\times {10}^{6}\\)\u003c/span\u003e\u003c/span\u003e/ml, the cells were stained using propidium iodide (PI) and RNase for 15min in darkness before being analyzed using a flow cytometer (Beckman Coulter, Inc., USA). CAL27, SCC15 and SCC9 were used for cell cycle analysis.\u003cb\u003eStatistical analysis\u003c/b\u003e\u003c/p\u003e \u003cp\u003eAll data were analyzed using GraphPad Prism 8.3.0 (GraphPad Software Inc., San Diego, CA, USA). The results are expressed as the mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard error of the mean. The results of two groups were compared using two-tailed Student t-test and three groups or more were compared using one-way ANOVA. The association of TRAIP and patient clinicopathologic characteristics was estimated using Wilcoxon rank-sum test. Statistical significance was marked using \u0026ldquo;*\u0026rdquo; to indicate P\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eTRAIP expression is upregulated in human TSCC tissues\u003c/h2\u003e \u003cp\u003eUsing the Human Protein Atlas (HPA) database, we found that TRAIP was expressed in various normal tissues (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). This result suggested that TRAIP expression is lower in normal tongue tissue and higher in testis, bone marrow or thymus. We further assessed the TRAIP expression level in HNSC using TCGA joint GTEx and GEO data and found that the expression level of TRAIP is all significantly higher in HNSC tissue than in normal tissue (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB-D). These results indicated a correlation between the high expression level of TRAIP and the tumorigenesis of HNSC. Based on the ROC curve, the cut-off value, AUC, sensitivity, specificity and Youden index were 2.284, 0.897, 0.743, 0.977 and 0.720, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE). These abovementioned data indicated that TRAIP may play an important role in HNSC diagnosis.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWe further studied the correlations between TRAIP expression and patient clinicopathological characteristics in human TSCC. The TRAIP expression in 9 pairs of fresh TSCC tumors and adjacent tissues was detected using western blot. The results suggested that TRAIP expression in tumor tissues was significantly higher than that in adjacent tissues, which indicated that TRAIP was up regulated in TSCC (P\u0026thinsp;\u0026lt;\u0026thinsp;0.01, Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF). Meanwhile, IHC findings showed that the expression level of TRAIP in TSCC tissues was higher than that in adjacent tissues (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG). TRAIP was located in the cytoplasm and cell membrane. The immuno-staining is strongly positive in lymph node metastasis than in primary tumor tissues (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG). In addition, the TRAIP expression level was higher in the primary tumors with lymph node metastasis than that without lymph node metastasis (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG). As shown in table 1, no significant association was observed between TRAIP expression and patients\u0026rsquo; gender, age and gross tumor type (P\u0026thinsp;\u0026gt;\u0026thinsp;0.05). However, the expression level of TRAIP evidently increased in stage III/IV compared with stage I/II, in carcinoma compared with adjacent tissue, in poor differentiation compared with well differentiation, in tissues with recurrence compared with those without recurrence, and in tissues with lymph node metastasis compared with thosewithout lymph node metastasis (P\u0026thinsp;\u0026lt;\u0026thinsp;0.05).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eTRAIP promotes TSCC cell proliferation and invasion\u003c/h2\u003e \u003cp\u003eA total of 19577 protein coding genes were obtained in TRAIP expression grouping (except TRAIP) and the volcano maps are shown in Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eA. By analyzing the abovementioned genes using GSEA, we obtained 389 entries in the C2 gene set and plotted the GSEA plots. The results indicated that TRAIP was related to the proliferation (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eB-C), invasion (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eD-E), and metastasis (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eF-H) of tumors, as well as DNA replication (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eI-J), EMT (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eK-L), cell cycle (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eM-O), and Wnt/β-catenin pathway (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eP).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWestern blot was used to detect the relative TRAIP expression in CAL27, SCC15 and SCC9 cells (Figure S2A). CAL27 and SCC15 showing a high expression level of TRAIP were selected for silencing TRAIP expression (Figure S2B). SCC9 showed the lowest expression level of TRAIP, which was used to overexpress TRAIP (Figure S2C). In studying the effect of TRAIP on TSCC, the expression level of TRAIP was silenced or overexpressed using lentiviruses. Proliferation assay and colony formation assay showed that cells with TRAIP silencing proliferated slowly and conversely, the cells selected to overexpress TRAIP grew faster (P\u0026thinsp;\u0026lt;\u0026thinsp;0.01, Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eA, B) compared with the NC group. Wound healing assay and Transwell assay revealed that TRAIP downregulation inhibited cell migration and invasion, but when TRAIP upregulated, the opposite applies (P\u0026thinsp;\u0026lt;\u0026thinsp;0.05, Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eC, D).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eIn exploring whether TRAIP influences the cell cycle progression in TSCC, groups with different TRAIP expression were involved. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003e, the percentage of cells increased in the G1 phase and decreased in the S phase in the shTRAIP group compared with the shNC group, and the trend was opposite in the TRAIP overexpressed group (P\u0026thinsp;\u0026lt;\u0026thinsp;0.05, Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eE), indicating that TRAIP induces G1 cell cycle arrest in TSCC cells.\u003c/p\u003e \u003cp\u003e \u003cb\u003eTRAIP knockdown inhibits tumor growth and metastasis\u003c/b\u003e \u003cb\u003ein vivo\u003c/b\u003e\u003c/p\u003e \u003cp\u003eIn conforming the effect of downregulated TRAIP on proliferation \u003cem\u003ein vivo\u003c/em\u003e, CAL27 cells with shTRAIP and shNC were planted to nude mice subcutaneously and injected into the tail vein of nude mice separately. Six weeks later, the weight of mice of the two groups didn\u0026rsquo;t have significant difference (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e3\u003c/span\u003eA). The tumor size in the experimental group was significantly smaller than that in the NC group (100.90\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\pm\\)\u003c/span\u003e\u003c/span\u003e31.95\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\({mm}^{3}\\)\u003c/span\u003e\u003c/span\u003evs.745.80\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\pm\\)\u003c/span\u003e\u003c/span\u003e153.84\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\({mm}^{3}\\)\u003c/span\u003e\u003c/span\u003e, P\u0026lt;0.05, Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e3\u003c/span\u003eB, C). In addition, the tumor weight in the experimental group was significantly less than that in the shNC group (196.80\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\pm\\)\u003c/span\u003e\u003c/span\u003e38.54mg vs. 1210.00\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\pm\\)\u003c/span\u003e\u003c/span\u003e179.22mg, P\u0026thinsp;\u0026lt;\u0026thinsp;0.05, Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e3\u003c/span\u003eD).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThe \u003cem\u003ein vivo\u003c/em\u003e bioluminescence imaging was used to detect metastasis in lung tissues. Three mice in the shTRAIP group had lung metastasis, whereas all five mice developed lung metastasis in the shNC group. The number of tumor foci detected in the shNC group was significantly more than that in the shTRAIP group (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e3\u003c/span\u003eE). Hematoxylin-eosin staining also confirmed this result (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e3\u003c/span\u003eF). These findings indicate that depleting TRAIP inhibits the proliferation and metastasis of TSCC cells \u003cem\u003ein vivo.\u003c/em\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003eDDX39A may be the interacting protein of TRAIP\u003c/h2\u003e \u003cp\u003eIn revealing the molecular mechanisms of TRAIP promoting TSCC progression, bioinformatics analysis, mass spectrometry and Co-IP were used. The flow chart is shown in figure S3. A total of 19,578 protein coding genes were obtained in patients with HNSC. The volcano maps are shown in Figure S4A. By taking the intersection of two differentially expressed genes and the results of mass spectrometry (table S2, table S3), and screening through the STRING database, 8 related genes were finally obtained (DNAJC9, RFC3, DDX18, CORO1C, ETF1, RFC4, DDX39A and PFDN2, Figure S4B-D). We found that RFC4 and DDX39A have higher relevance with TRAIP by analyzing the correlation between the abovementioned 8 genes and TRAIP (Figure S4E-M, table S4). Considering that the relationship between RFC4 and TSCC has been revealed[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e], we selected DDX39A for the subsequent experiment.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThe relationship between TRAIP and DDX39A was confirmed by Co-IP (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eA, B). Figure\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eA shows that DDX39A was one of the proteins that bind to TRAIP. Figure\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eB shows that TRAIP was also one of the proteins that bind to DDX39A. The DDX39A protein levels were decreased when TRAIP was knocked down in TSCC cell lines (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eC). On the contrary, the DDX39A protein level increased when TRAIP was overexpressed (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eD). When DDX39A was silenced or upregulated, the expression level of TRAIP was also downregulated or overexpressed (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eE, F).In addition, truncated bodies mutually experiments show that the HELICc domain of DDX39A is the necessary structure for the interaction between DDX39A and TRAIP region (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003eG,H)\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eTRAIP promotes TSCC cell proliferation and invasion by increasing DDX39A expression\u003c/h2\u003e \u003cp\u003eAs shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e4\u003c/span\u003e, DDX39A knockdown inhibited cell proliferation (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e5\u003c/span\u003eA,B), cell cycle progression (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e5\u003c/span\u003eC-D, Figure S5A), migration, invasion (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e5\u003c/span\u003eE-J, Figure S5B) and caused G1 cell cycle arrest, and when DDX39A was overexpressed, the results were opposite. In determiningthe relationship between DDX39A and TRAIP in TSCC progression, rescue experiments were performed. DDX39A was overexpressed in TRAIP-knockdown cells and DDX39A was silenced in TRAIP overexpressed cells. Transwell assays indicated that DDX39A overexpression (partly) rescued the migration and invasion abilities in TRAIP-knockdown cells, and DDX39A silencing decreased the migration and invasion abilities caused by TRAIP overexpression (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e5\u003c/span\u003eK,L). These results suggested that TRAIP interacted with DDX39A during TSCC progression.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eTRAIP and DDX39A induces EMT in TSCC cells\u003c/h2\u003e \u003cp\u003eWestern blot analysis showed that when TRAIP or DDX39A was suppressed, the protein levels of N-cadherin, Vimentin, Slug, Snail, MMP-2 and MMP-9 were decreased, and E-cadherin expression didn\u0026rsquo;t have obvious change (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e6\u003c/span\u003eA,-F). When TRAIP or DDX39A was upregulated, the expression level of N-cadherin, Vimentin, Slug, Snail, MMP-2 and MMP-9 was increased, and E-cadherin expression still didn\u0026rsquo;t remarkably change (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e6\u003c/span\u003eG-J). The overexpression of DDX39A might increase the expression level of EMT related proteins (except for E-cadherin) caused by TRAIP suppression (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e6\u003c/span\u003eK,L). In addition, the downregulation of DDX39A can decrease the expression level of EMT related proteins (except for E-cadherin) caused by TRAIP overexpression (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e6\u003c/span\u003eM,N).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003eDDX39A and TRAIP regulated proliferation, migration and invasion via Wnt/β-catenin pathway in TSCC cells\u003c/h2\u003e \u003cp\u003eIn exploring the mechanism of TRAIP and DDX39A in regulating cell progression in TSCC, we analyzed the protein levels of Wnt/β-catenin pathway. TRAIP or DDX39A silencing decreased the expression level of P-β-catenin, cyclinD1 and c-Myc, but β-catenin expression level didn\u0026rsquo;t significantly change (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e7\u003c/span\u003eA-F). Conversely, the expression level of P-β-catenin, cyclinD1 and c-Myc was increased after TRAIP or DDX39A overexpression, and β-catenin expression level still didn\u0026rsquo;t significantly change (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e7\u003c/span\u003eG-J). The overexpression of DDX39A might enhance the expression level of P-β-catenin, cyclinD1 and c-Myc caused by TRAIP suppression (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e7\u003c/span\u003eK,L). Moreover, the downregulation of DDX39A can diminish the expression level of related proteins caused by TRAIP overexpression (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e7\u003c/span\u003eM,N). The diagram was plotted using Biorender (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://biorender.com/\u003c/span\u003e\u003cspan address=\"https://biorender.com/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e, Fig.\u0026nbsp;\u003cspan refid=\"Fig13\" class=\"InternalRef\"\u003e8\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eAt present, the main treatment of tongue carcinoma is surgery, and chemoradiation is also important in advanced stage patients[\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. However, these treatments damage patients\u0026rsquo; appearance, cause psychosocial problems, and lead to functional defect, particularly dysphagia[\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. Some other severe complications are found in these therapies, which seriously influence the quality of life. Therefore, exploring ways at a molecular level is of great importance to improve patient prognosis.\u003c/p\u003e \u003cp\u003eAs a post-translational modification of proteins, ubiquitination plays an important role in many biological functions, such as proliferation, apoptosis and differentiation[\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. TRAIP is an E3 ubiquitin ligase, which has a RING finger motif and an extended coiled-coil domain[\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. Bioinformatics and previous studies have pointed that TRAIP is involved in cell progression. In addition, TRAIP plays an important role in regulating replisome stability and DNA interstrand cross-links repair pathway option[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. Considering the mammalian replicative stress response and as a factor interacting with the proliferation cell nuclear antigen, TRAIP contributes to the recovery of impaired DNA replication forks[\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e]. TRAIP regulates mitotic process by regulating the spindle assembly checkpoint and it\u0026rsquo;s crucial to early mitotic process and arrangement of metaphase chromosomes[\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. Our research suggested that TRAIP is highly expressed in TSCC and closely related to the prognosis of patients. Therefore, TRAIP might promote the malignant behavior of TSCC. Our \u003cem\u003ein vivo\u003c/em\u003e and \u003cem\u003ein vitro\u003c/em\u003e experimental results also showed that TRAIP may stimulate the proliferation, migration and invasion of TSCC cells. Reports had suggested that TRAIP overexpression can increase the cell proliferation and metastatic ability in liver cancer, lung cancer, osteosarcoma and triple-negative breast cancer[\u003cspan additionalcitationids=\"CR11\" citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e], these findings were consistent with our experimental results. However, TRAIP plays the opposite role in some tumors[\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. In choroidal melanoma, TRAIP overexpression weakens the ability of choroidal melanoma cells to proliferate, migrate and invade and inhibits EMT progression because of its ability to ubiquitinate Twist1, thereby mediating its proteasomal degradation[\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. Kong LR et al. showed that TRAIP dephosphorylates IĸB and impedes the nuclear translocation of RelA (p65), thereby repressing oncogenic nuclear factor kappa-B (NF-ĸB) signaling and inducing apoptosis[\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. This condition can often be explained by the fact that the same gene may play different roles in different types of tumors, such as DNA-binding protein inhibitor 4 (ID4). In prostate cancer, ID4 is epigenetically silenced and acts as a tumor suppressor[\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. However, ID4 is a potential oncogene in bladder cancer and colorectal cancer[\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. In addition, studies have shown that in some cases, the high expression of the tumor suppressor PTEN may lead to the proliferation and invasion of pre-B acute lymphoblastic leukemia cells, resulting in a poor prognosis[\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. These studies suggest that the role and impact of a gene may vary depending on factors such as cell type, tumor type and genetic environment.\u003c/p\u003e \u003cp\u003eOur research also showed that silencing TRAIP induces G1 cell cycle arrest in TSCC cells, which consists with the role of TRAIP in foreskin keratinocyte[\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. After silencing TRAIP or DDX39A, the expression of cyclinD1 was decreased. The main function of cyclinD1 is to promote cell proliferation[\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. CyclinD1 binds to and activates the G1-phase unique cyclin-dependent kinase CDK4, which is phosphorylated by the G1 phase cycle inhibitor protein (Rb). Moreover, the phosphorylated Rb protein is dissociated from the E2F transcription factor to which it binds, and the E2F transcription factor initiates the transcription of genes in the living cell cycle, thereby promoting the cell cycle from the G1 phase to the S phase[\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e, \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. We hypothesized that TRAIP and DDX39A cause cell cycle arrest by inhibiting cyclinD1 expression.\u003c/p\u003e \u003cp\u003eIn this study, mass spectrometry, bioinformatics and Co-IP were used to identify the factor that plays a role with TRAIP in the progression of TSCC and DDX39A was selected. DDX39A belongs to the DEAD RNA helicase family, which is related to several cell processes, such as cells growth, migration, apoptosis, cytoskeletal rearrangement and RNA translocation[\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]. Reports have suggested that DDX39A promotes cell growth and metastasis in hepatocellular carcinoma, melanoma and lung squamous cell carcinoma[\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. However, DDX39A inhibits the invasion ability of bladder cancer cells[\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e]. These studies suggest that DDX39A may play completely opposite roles in different tumors. By performing bioinformatics analysis, we found that DDX39A was highly expressed in TSCC tissue compared with normal tissue. We prove that DDX39A is the interacting protein of TRAIP, and HELICc domain of DDX39A is the key to interact with TRAIP.The interaction of TRAIP and DDX39A can regulate the proliferation, migration, invasion abilities and cell cycle progression in TSCC. Furthermore, our results showed that DDX39A and TRAIP enhanced TSCC migration and invasion via EMT pathway and Wnt/β-catenin signaling. Reports have indicated that DDX39A was highly expressed in several carcinomas, which can promote tumors progression, for instance, renal clear cell carcinoma, melanoma, hepatocellular carcinoma and breast cancer[\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e, \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e]. These studies were in accordance with our findings. DDX39A was also related to chemoresistance in ER positive breast cancer and human pancreatic cancer[\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e]. This protein may be an important immune checkpoint for it can cause tumor immune escape in renal clear cell carcinoma[\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]. Therefore, the interaction of TRAIP and DDX39A is of great importance in TSCC progression.\u003c/p\u003e \u003cp\u003eThe Wnt/β-catenin pathway is crucial to cell proliferation and metastasis, and during the activation of Wnt/β-catenin pathway, β-catenin accumulates in the cytoplasm, then enters the nucleus and interacts with T-cell factor/lymphoid enhancer factor (TCF/LEF), activating Wnt target genes, leading to tumorigenesis and metastasis[\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e]. EMT is a key process of cancer cell metastasis, during which epithelial cells acquired the characteristics of mesenchymal cells, enhanced cell motility and increased migration ability[\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. Research showed that DDX39A promotes hepatocellular carcinoma growth and metastasis by activating Wnt/β-catenin pathway[\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. However, studies related to DDX39A and EMT have not been reported. Our research indicated that TRAIP and DDX39A could regulate cell progression through EMT and Wnt/β-catenin pathway.\u003c/p\u003e \u003cp\u003eUp to now, this study is the first to investigate (1) TRAIP expression in TSCC and its relationship with clinicopathological characteristics of TSCC patients, (2) the effect of TRAIP and DDX39A on progression of TSCC cells, (3) the interaction of TRAIP and DDX39A in TSCC progression, (4) the mechanism by which the two factors regulate tumor malignant behaviors. Our research indicates that TRAIP and DDX39A may be potential treatment targets in TSCC.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research was supported by the Natural Science Foundation of Shandong Province (ZR2022MH206), the National Natural Science Foundation of China (No.81672606), and Beijing Jingjian Pathology Development Foundation (JJlXA2022-008).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll data from this study are available from the corresponding author.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCW was responsible for the conception and design. PW, LL and CG contributed to the experimental performance. LS, LC, HQ and YZ were responsible for data analysis. PW, CW and XX were responsible for manuscript writing and revision.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe\u0026nbsp;research\u0026nbsp;protocol was approved by the\u0026nbsp;Medical\u0026nbsp;Ethical Committee of\u0026nbsp;the Affiliated\u0026nbsp;Hospital of\u0026nbsp;Qingdao\u0026nbsp;University (registration no.\u0026nbsp;QYFY WZLL 27524)\u0026nbsp;and Qingdao University Laboratory Animal Welfare Ethics Committee\u0026nbsp;(registration no.\u0026nbsp;20210420BALB/Cnude100615001).\u0026nbsp;All patients or their guardians were given and accepted informed consent.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePatient consent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll patients or their guardians\u0026nbsp;gave\u0026nbsp;consent\u0026nbsp;to publication.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDeclaration of interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declared no conflict of interest.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eWarnakulasuriya S, Kerr AR. Oral Cancer Screening: Past, Present, and Future. J Dent Res. 2021;100(12):1313\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePillai J, et al. A systematic review of proteomic biomarkers in oral squamous cell cancer. World J Surg Oncol. 2021;19(1):315.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLenze NR, et al. Age and risk of recurrence in oral tongue squamous cell carcinoma: Systematic review. Head Neck. 2020;42(12):3755\u0026ndash;68.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang K, et al. LUCAT1 as an oncogene in tongue squamous cell carcinoma by targeting miR-375 expression. J Cell Mol Med. 2021;25(10):4543\u0026ndash;50.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWikner J, et al. Squamous cell carcinoma of the oral cavity and circulating tumour cells. World J Clin Oncol. 2014;5(2):114\u0026ndash;24.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8(9):11884\u0026ndash;94.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBonomo P, et al. Quality Assessment in Supportive Care in Head and Neck Cancer. Front Oncol. 2019;9:926.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRinkel RN, et al. Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI. Eur Arch Otorhinolaryngol. 2016;273(7):1849\u0026ndash;55.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChapard C, Hohl D, Huber M. The role of the TRAF-interacting protein in proliferation and differentiation. Exp Dermatol. 2012;21(5):321\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuo Z, et al. TRAIP promotes malignant behaviors and correlates with poor prognosis in liver cancer. Biomed Pharmacother. 2020;124:109857.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu Y, et al. LncRNA SLC7A11-AS1 Contributes to Lung Cancer Progression Through Facilitating TRAIP Expression by Inhibiting miR-4775. Onco Targets Ther. 2020;13:6295\u0026ndash;302.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi M, et al. TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation. Cell Death Dis. 2021;12(8):767.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZheng Y, et al. Silencing TRAIP suppresses cell proliferation and migration/invasion of triple negative breast cancer via RB-E2F signaling and EMT. Cancer Gene Ther. 2023;30(1):74\u0026ndash;84.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePark ES, et al. Early embryonic lethality caused by targeted disruption of the TRAF-interacting protein (TRIP) gene. Biochem Biophys Res Commun. 2007;363(4):971\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRegamey A, et al. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med. 2003;198(12):1959\u0026ndash;64.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen C, Huang H, Wu CH. Protein Bioinformatics Databases and Resources. Methods Mol Biol. 2017;1558:3\u0026ndash;39.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eReyes M et al. Wnt/β-Catenin Signaling in Oral Carcinogenesis. Int J Mol Sci, 2020. 21(13).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVivian J, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhuang Z, et al. Down-Regulation of Long Non-Coding RNA TINCR Induces Cell Dedifferentiation and Predicts Progression in Oral Squamous Cell Carcinoma. Front Oncol. 2020;10:624752.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEdgar R, Domrachev M, Lash AE. \u003cem\u003eGene Expression Omnibus: NCBI gene expression and hybridization array data repository.\u003c/em\u003e Nucleic Acids Res, 2002. 30(1): pp. 207\u0026thinsp;\u0026ndash;\u0026thinsp;10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRobin X, et al. pROC: an open-source package for R and S\u0026thinsp;+\u0026thinsp;to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLove MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWu T, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2(3):100141.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang C, et al. Silencing of KIF3B Suppresses Breast Cancer Progression by Regulating EMT and Wnt/β-Catenin Signaling. Front Oncol. 2020;10:597464.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang J, Wang L, Xie X. RFC4 promotes the progression and growth of Oral Tongue squamous cell carcinoma in vivo and vitro. J Clin Lab Anal. 2021;35(5):e23761.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGonzalez M, Riera March A. \u003cem\u003eTongue Cancer\u003c/em\u003e, in \u003cem\u003eStatPearls\u003c/em\u003e. 2021, StatPearls Publishing Copyright \u0026copy; 2021, StatPearls Publishing LLC.: Treasure Island (FL).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCohen Goldemberg D et al. \u003cem\u003eTongue cancer epidemiology in Brazil: incidence, morbidity and mortality.\u003c/em\u003e 2018. 40(8): pp. 1834\u0026ndash;1844.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang ZS, et al. Dysphagia in Tongue Cancer Patients Before and After Surgery. J Oral Maxillofac Surg. 2016;74(10):2067\u0026ndash;72.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from structures to functions. Nat Rev Mol Cell Biol. 2009;10(10):659\u0026ndash;71.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWelchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 2005;6(8):599\u0026ndash;609.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee SY, Lee SY, Choi Y. TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J Exp Med. 1997;185(7):1275\u0026ndash;85.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWu RA, et al. TRAIP is a master regulator of DNA interstrand crosslink repair. Nature. 2019;567(7747):267\u0026ndash;72.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFeng W, et al. TRAIP regulates replication fork recovery and progression via PCNA. Cell Discov. 2016;2:16016.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChapard C, et al. TRAIP is a regulator of the spindle assembly checkpoint. J Cell Sci. 2014;127(Pt 24):5149\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWei C, et al. TRIP suppresses cell proliferation and invasion in choroidal melanoma via promoting the proteasomal degradation of Twist1. FEBS Lett. 2020;594(19):3170\u0026ndash;81.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKong LR et al. \u003cem\u003eTargeting codon 158 p53-mutant cancers via the induction of p53 acetylation.\u003c/em\u003e Nat Commun, 2020. 11(1): p. 2086.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKomaragiri SK, et al. ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells. Biochem Biophys Res Commun. 2016;478(1):60\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOu D, et al. miR-340-5p affects oral squamous cell carcinoma (OSCC) cells proliferation and invasion by targeting endoplasmic reticulum stress proteins. Eur J Pharmacol. 2022;920:174820.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShojaee S, et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016;22(4):379\u0026ndash;87.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSerrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGoel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22(6):356\u0026ndash;72.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNarita M, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113(6):703\u0026ndash;16.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChan CH, et al. DNA Damage, Liver Injury, and Tumorigenesis: Consequences of DDX3X Loss. Mol Cancer Res. 2019;17(2):555\u0026ndash;66.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang T, et al. DDX39 promotes hepatocellular carcinoma growth and metastasis through activating Wnt/β-catenin pathway. Cell Death Dis. 2018;9(6):675.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKato M, et al. DDX39 acts as a suppressor of invasion for bladder cancer. Cancer Sci. 2012;103(7):1363\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBao Y, et al. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma. Int J Biol Sci. 2021;17(12):3158\u0026ndash;72.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang X, et al. DEAD-box RNA Helicase 39 Promotes Invasiveness and Chemoresistance of ER-positive Breast Cancer. J Cancer. 2020;11(7):1846\u0026ndash;58.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKuramitsu Y, et al. Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells. Anticancer Res. 2013;33(8):3133\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006;281(32):22429\u0026ndash;33.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNieto MA, et al. EMT: 2016. Cell. 2016;166(1):21\u0026ndash;45.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 1 is available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"TRAIP, Progression, Tongue squamous cell carcinoma, Wnt/β-catenin signaling, EMT, DDX39A","lastPublishedDoi":"10.21203/rs.3.rs-4266683/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4266683/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eTongue squamous cell carcinoma (TSCC) is one of the most common malignant tumors with high mortality and poor prognosis. Its incidence rate is increasing gradually. Tumor necrosis factor receptor-associated factor interacting protein (TRAIP), as a factor related to several tumors, reveals that its gene expression is different between normal tissue and primary tumor of head and neck squamous cell carcinoma using bioinformatics analysis.\u003c/p\u003e\u003ch2\u003eMethod\u003c/h2\u003e \u003cp\u003eIn our study, TCGA database, immunohistochemistry, proliferation assay, colony formation, wound healing assay, Transwell, cell cycle analysis and tumor xenografts model were used to determine the expression and functions of TRAIP in TSCC.\u003c/p\u003e\u003ch2\u003eResult\u003c/h2\u003e \u003cp\u003eWe found that TRAIP may promote the proliferation, migration and invasion of TSCC. Furthermore, the results of bioinformatics analysis, mass spectrometry and co-immunoprecipitation suggested that DDX39A may be a TRAIP interacting protein. DDX39A has been proven to be an oncogene in several tumors, which may have an important effect on cell proliferation and metastasis in multiple tumors. In addition, the high expression of DDX39A implies the poor prognosis of patients. Our study demonstrated that TRAIP probably interact with DDX39A to regulate cell progression through epithelial-mesenchymal transition and Wnt/β-catenin pathway.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eThese results indicate that TRAIP is important in occurrence and development of TSCC and is expected to become the new promising therapeutic target.\u003c/p\u003e","manuscriptTitle":"TRAIP enhances progression of tongue squamous cell carcinoma through EMT and Wnt/β-catenin signaling by interacting with DDX39A","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-04-25 16:47:20","doi":"10.21203/rs.3.rs-4266683/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-04-24T13:32:33+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-04-24T13:06:55+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-04-18T04:17:20+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Cancer","date":"2024-04-15T01:55:47+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1273cb2b-0e10-42d7-ac3b-edf78ffa4528","owner":[],"postedDate":"April 25th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-12-09T15:59:32+00:00","versionOfRecord":{"articleIdentity":"rs-4266683","link":"https://doi.org/10.1186/s12885-024-13130-8","journal":{"identity":"bmc-cancer","isVorOnly":false,"title":"BMC Cancer"},"publishedOn":"2024-12-02 15:57:03","publishedOnDateReadable":"December 2nd, 2024"},"versionCreatedAt":"2024-04-25 16:47:20","video":"","vorDoi":"10.1186/s12885-024-13130-8","vorDoiUrl":"https://doi.org/10.1186/s12885-024-13130-8","workflowStages":[]},"version":"v1","identity":"rs-4266683","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4266683","identity":"rs-4266683","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}